When a hospital runs out of an antibiotic, a cancer drug, or an anaesthetic, the failure isn’t clinical, it’s industrial. A single factory closure in Asia, a geopolitical rupture, or a global bidding war can strip a ward of tools doctors have trained their careers to use. The European Commission’s proposed Critical Medicines Act EU framework, published on 11 March 2025, is Brussels’ binding answer to that fragility, and it goes further than guidance.
The proposal is a regulation. If adopted by the European Parliament and Council, it carries full legal force across all 27 Member States.
How the Critical Medicines Act EU Plans to Rebuild Supply
The Act rests on four pillars. First, designated “Strategic Projects” industrial initiatives that create or expand EU manufacturing capacity for critical medicines or their active pharmaceutical ingredients. These projects unlock fast-tracked regulatory and scientific support, plus easier pathways to public funding.
Second, newly published state aid guidance gives Member States a clearer legal basis to financially back those projects without violating EU competition rules, a friction point that has historically paralysed national investment in domestic pharma.
Third, public procurement gets a structural overhaul. Buyers, hospitals, procurement agencies, and health authorities face mandatory requirements to diversify input sources and monitor supply chains. Where dependency on a single country is high, they must actively favour EU-produced alternatives. This converts purchasing decisions into direct industrial policy.
Fourth, the Commission will facilitate collaborative procurement across Member States, pooling their collective buying power, and explore international partnerships to widen supply beyond Europe’s borders.
“Medicine shortages and structural dependencies in our pharmaceutical supply chains put the health of Europeans at risk. Today’s Critical Medicines Act is a key initiative to improve access and availability to medicines for everyone in the EU, and to strengthen our health security.” Says Commissioner for Health Olivér Várhelyi.
EU critical medicines manufacturing also confronts a real-world constraint: building validated pharmaceutical facilities takes years, requires specialist workforces, and demands regulatory clearance at every stage. “Fast-tracked” support for Strategic Projects helps at the margins; it does not compress a decade-long industrial rebuild into one Commission term.
The new mandatory tender requirements add compliance layers, documented API origin checks, supply chain monitoring reports, and justifications when cheaper non-EU options are chosen. That is more administrative work, but it also gives buyers a legal lever to prioritise resilience over the lowest price.
The EU critical medicines pharmaceutical supply chain debate has run since COVID-19 exposed how thin the margins were. This Act is the Commission’s most concrete industrial-policy response: binding procurement rules, funding pathways, and a formal project designation manufacturers can build a business case around.
Whether it moves fast enough to matter before the next shortage arrives is a question the legislation itself cannot answer.
